Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19

Next Previous
Trial Profile

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Travatrelvir (Primary) ; Nirmatrelvir+ritonavir
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Traws Pharma

Most Recent Events

  • 22 Oct 2025 According to Expert Systems Inc media release, the company will support Traws Pharma Phase 2 Clinical Studies of Ratutrelvir treat newly diagnosed COVID-19 patients.Following successful completion of Phase 1 safety and PK studies, regulatory approval was granted for Phase 2 initiation in Q3 2025.
  • 14 Oct 2025 According to Traws Pharma media release, company's expectation is to be able to report the results of both Phase 2 studies by year end 2025.
  • 14 Oct 2025 According to Traws Pharma media release, the company announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free anti-viral treatment in newly diagnosed COVID subjects.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top